Creating a Hybrid Care Plan for Heart Failure Patients

Soundos Moualla, MD, FACC, FSCAI
Interventional Cardiology
Dignity Health, Yavapai Regional Medical Center

Congestive heart failure (CHF) results in poor patient outcomes and increases the cost of care particularly with recurrent CHF hospitalizations. Using the CardioCare platform, we have started prospectively cross-matching the CardioCare alerts with hospital heart failure admissions for both aortic stenosis (AS) and mitral regurgitation (MR) patients. This has allowed us to provide better patient care by creating a daily alert system, that improved communication and coordination of care with the heart failure team at Dignity Health, Yavapai Regional Medical Center. This process led to more expeditious care of acutely ill patients, subsequently reducing re-admission rates of patients with congestive heart failure.

In the last year, 224 patients diagnosed with severe mitral regurgitation were also admitted to the hospital with heart failure. With this data, our team created a hybrid care plan among multiple clinical disciplines to increase disease awareness, implement therapeutic interventions based on guidelines, and improve the outcomes of this patient population.

Below is an example of sample data from the CardioCare platform, with reconciled plan of care:

 *Illustrative Data

In addition to the approach above, we plan to further collaborate with the heart failure team to look at patients with retrospective CHF admissions; specifically recurrent CHF admissions, and cross-match with aortic stenosis and mitral regurgitation patients from CardioCare.  We anticipate that we will identify patients with untreated valve pathologies (AS and/or MR) with recurrent CHF exacerbations, who previously have not been under the care of the structural heart or heart failure teams. The aim is to ensure these patients are managed appropriately with guideline directed medical therapy, appropriate valvular therapies, and followed appropriately. It is critical for community structural heart programs to have a multifaceted approach to cardiovascular patient care, striving to improve the standards for physicians, allied health organizations, and most importantly patients.

Related Articles

AI Alliance

What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams 

On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.

Real-World Evidence

Acute Valve Syndrome in Aortic Stenosis

“These findings are extremely important and complementary to the recently presented EARLY TAVR Trial, published in the NEJM. The absence of symptoms was traditionally considered a sign of relative safety. However, this study shows how frequent acute valve syndrome is in patients undergoing AVR, and how patients would benefit greatly

Press

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR) Key Findings Demonstrate 3x Improved Survival for Asymptomatic AS Patients Undergoing AVR versus AS Patients Presenting with Acute Valve Syndrome ALISO VIEJO, Calif. – October 28, 2024 – egnite, Inc., a leading cardiovascular digital